Washington University trial studies antidepressant Fluvoxamine as treatment for Long COVID symptoms (Links to an external site)

ST. LOUIS (KMOV) -A clinical trial at the Washington University School of Medicine is studying the impact of an antidepressant on long COVID symptoms.

Specifically, the study is examining whether Fluvoxamine, a medication used to treat depression and obsessive-compulsive disorder, can relieve problems with “brain fog” and other neurological conditions associated with lingering symptoms.

Update on our study of an early treatment COVID-19

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial Eric J. Lenze, MD1; Caline Mattar, MD2; Charles F. Zorumski, MD1; Angela Stevens, BA1; Julie Schweiger1; Ginger E. Nicol, MD1; J. Philip Miller, AB3; Lei Yang, MPH, MSIS1; Michael Yingling, MS1; Michael S. Avidan, MBBCh4; Angela M. Reiersen, MD, MPE1JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.22760